Latest Headlines

Latest Headlines

Which drugs win the script popularity contest? Crestor, Synthroid and Nexium

If we could see inside every medicine chest in the United States, which pill bottles or delivery devices would we see most often? Some numbers from the IMS Institute for Healthcare Informatics, reported by Medscape, tell us just that.

How to sell a statin? Pfizer and AstraZeneca have different ideas

It's a tale of two statin drugs and their attempts to keep market share--or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay discount program, and this time, it applies to patients covered via certain U.S. government programs.

AstraZeneca's Crestor gets a boost from Cigna data-crunching deal

Insurance giant Cigna inked a deal with AstraZeneca to allow its brand-name statin drug Crestor to be prescribed without prior authorization--provided a computer model says a patient needs it.

AstraZeneca wins FDA OK for another fish-oil heart pill, enters crowded market

AstraZeneca has won FDA approval for its new prescription strength fish oil therapy for artery-clogging fats, but don't look for it to help much in its nascent effort to convince investors that its bright prospects should make them steer clear of Pfizer's takeover pitch. This drug is headed into a crowded field that now includes a low-priced generic competitor.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Statins and muscle aches are unrelated

So is Lipitor or Crestor causing you to have muscle aches? The answer is no, according to a new meta-analysis of the side effects of the cholesterol-lowering drugs.

AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines

New rules for prescribing statin drugs could double the number of people taking them--or not. They could help AstraZeneca pump up sales of its high-powered Crestor--or not. What they will do--most likely--is undercut Merck's cholesterol drugs Vytorin and Zetia, along with AbbVie's fenofibrate-based lipid meds TriCor and Trilipix.

Study: Pharma payments do sway doctors' prescribing habits

A new study shows that payments do influence doctors' behavior. The average amount that flows from pharma to physician is about $1,700 per. Still, doctors are swayed by free dinners and speaking fees, the study finds, with prescriptions rising along with payments.

Analysts skeptical as AstraZeneca sales, earnings sink

AstraZeneca's first-quarter sales dropped by 12%. Core earnings fell by 21%. Neither number approached Bristol-Myers Squibb's scary declines. Both companies are suffering big-time hits to their top drugs, because of generic competition. AstraZeneca's earnings actually beat expectations. So why are AstraZeneca analysts less positive about the company's results? It's all about the future.

AstraZeneca zaps another Crestor generic threat with Actavis settlement

AstraZeneca has wrapped up another Crestor patent fight. Two generics makers, Actavis and Egis, admitted that the cholesterol drug's patent is valid. And in return, AstraZeneca agreed to share the market in May 2016, 67 days before its pediatric exclusivity expires.